74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Smith & Nephew PLC
Closed
1,033 1.67
Overview
Share price change
24h
Min
1028.5
Max
1033.5
Income | 107M |
|---|---|
Sales | 1.4B |
P/E Sector Avg | 36.482 29.356 |
Dividend yield | 2.87 |
Profit margin | 7.57 |
Employees | 18,000 |
EBITDA | 260M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +22.28 upside |
Dividend yield Sector Avg | 2.87% 5.39% |
|---|---|
Next Earnings | 25 Feb 2025 |
Market Cap | -116M 8.9B |
|---|---|
Previous open | 1031.33 |
Previous close | 1033 |
Smith & Nephew PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Smith & Nephew PLC Forecast
Price Target
By TipRanks
22.28% upside
12 Months Forecast
Average 1,263.75 GBX 22.28%
High 1,350 GBX
Low 1,170 GBX
Based on 4 Wall Street analysts offering 12 month price targets forSmith & Nephew PLC - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.